

# The Microbial Pharmacy: FDA Approved Medicines From Fungi

Shannon Langdon and Cedric J. Pearce, Ph.D.  
Mycosynthetix, Inc.

Millions of patients with life threatening diseases are treated each year with medicines made by fungi. In fact, the medicinal value of fungal metabolites has been known for centuries; this is summarized in Table 1. From both a humanitarian view and from a market perspective, medicines produced by fungi are very valuable.

Records show that the earliest medicinal use of fungi recorded is red yeast rice, which was developed in China around 800 AD.<sup>(1)</sup> By cultivating a yeast (*Monascus purpurea*) in rice a pharmaceutically-active mixture of compounds is produced. Initially, this was carried out by people who were not mycologists.

Chemical analysis of red yeast rice products late in the 20th century showed that they contain a variety of organic compounds related to statins as well as Compactin, also known as Mevastatin®, the first statin approved by the US FDA for clinical use for the reduction of blood cholesterol levels in patients.<sup>(2)</sup> The Chinese claimed that red yeast rice had a variety of biological activities, including being useful to treat cardiovascular problems.<sup>(1)</sup>

The second historic and commonly used fungal product, although not at that time as a medicine in the strictest sense, are the psilocybin-containing mushrooms such as *Psilocybe mexicana*, which were used in religious ceremonies by the Aztec indians of Central America, and by other religions throughout the world.<sup>(3)</sup> Psilocybin has subsequently been evaluated clinically to address stress and related symptoms associated with terminal illness.<sup>(4)</sup>

In 1928 Alexander Fleming, a physician working at St Mary's hospital in London, observed the effect of penicillin, produced by *Penicillium notatum* which was a contaminant growing on a Staphylococcus containing Petri dish.<sup>(5)</sup> Penicillin (penicillin V was the first member of the penicillin family to be discovered) was subsequently isolated and characterized by a trans-Atlantic collaborative effort, which resulted in the first true antibiotic becoming widely available. Today penicillin yields from *Penicillium* are approximately 14,000 times higher than those initially observed by Fleming, and current yields in excess of 70 grams per liter of fermentation are claimed.<sup>(6,7)</sup> Through a variety of medicinal chemistry and fermentation approaches, hundreds of penicillins have been prepared and tested.

One semi-synthetic penicillin, amoxicillin, together with the *Actinomyces*-product clavulanic acid, is available as Augmentin® and used clinically for animal and human infection control. The antibiotic mixture works as follows; clavulanic acid overcomes the problem of antibiotic-resistant pathogenic bacteria producing an enzyme, beta-lactamase, which destroys the activity of penicillin. Clavulanic acid inactivates the beta-lactamase enzyme thereby

protecting the penicillin and leaving the intact antibiotic able to produce the desired effect of killing the bacteria.

Cephalosporin, a second member of the beta-lactam antibiotic family, was discovered from a fungus, *Cephalosporium* isolated from a sewer outlet off the coast of Sardinia in 1948 by Italian scientist Giuseppe Brotzu.<sup>(8)</sup> The natural cephalosporin was never used clinically, but analogues were prepared with superior antibacterial activity. There have been multiple generations of cephalosporins, each with improved activity and applications.

A third clinically important antibiotic produced by fungi is the steroid fusidic acid. This compound is derived from the fungus *Fusidium coccineum*, and was developed in the early 1960s by the Danish drug company Leo Pharma.<sup>(9)</sup> It was introduced clinically for the treatment of Gram positive bacterial infections.

Shiitake mushrooms, which are native to East Asia, are cultivated worldwide for their health benefits. Shiitake mushrooms contain lentinan, a polysaccharide thought to be responsible for these health benefits. Lentinan has been studied extensively in the laboratory, and has been shown to be effective in enhancing the immune system.<sup>(10)</sup> It has also been shown to kill microbes and viruses.<sup>(11)</sup> Compounds from shiitakes have also been shown to lower cholesterol in laboratory studies.<sup>(12)</sup>

Ergotamine is a vasoconstricting ergot alkaloid from *Claviceps purpurea*. Ergotamine is used to treat migraine type headaches.<sup>(13)</sup> It was first isolated by Arthur Stoll at Sandoz (now Novartis) in 1918.<sup>(14)</sup> Use of this fungus medicinally began in the 16th century, when it was used to accelerate parturition.<sup>(15)</sup> Ergotamine is sometimes administered in combination with caffeine to treat migraine headaches.<sup>(16)</sup>

Lysergic acid was found from *Claviceps purpurea* in 1938.<sup>(17)</sup> Although not particularly active itself, lysergic acid diethylamide (LSD) is a highly potent CNS active compound producing hallucinations in those who take it. An account of the discovery of LSD by Albert Hofmann, who accidentally consumed LSD while preparing analogues of lysergic acid in the lab, is given in "LSD My Problem Child: Reflections on Sacred Drugs, Mysticism and Science."<sup>(18)</sup> The comments from his supervisor at the time, which addressed the accuracy of the reported amount ingested

with no mention of laboratory hygiene, together with a comment on potency, is a stark reminder of how things have changed in lab protocol over the past half century. What was considered as normal behavior in a lab in the 1940s would result in a scientist being ejected today.

It is also interesting that fungi have been the source of two of the best known hallucinogens, both of which are currently, or have been, used in clinical trials to treat terminally ill patients.<sup>(19-22)</sup>

Cyclosporin A, a powerful immunosuppressant used following organ transplant to overcome the issues of organ rejection by the new host, was initially found from *Tolypocladium inflatum* as an anti fungal agent by Sandoz research workers.<sup>(23)</sup> Further *in vivo* evaluation showed it had immunosuppressive activity. Cyclosporin A is a cyclic peptide, MW 1202.61 grams/mol, and is biosynthesized by one of the largest enzyme complexes known. Current sales of cyclosporin are in excess of one billion dollars in the USA alone.<sup>(24)</sup> A number of semi-synthetic cyclosporins with significant biological activity including anti viral have been discovered.

There are a number of other microbial metabolites with immunosuppressive activity including mycophenolic acid which was first isolated from *Penicillium stoloniferum* over 100 years ago.<sup>(25)</sup> Mycophenolic acid inhibits purine biosynthesis and effects B and T lymphocyte proliferation.<sup>(26, 27)</sup> Mycophenolic acid, as the mofetil derivative, is marketed as CellCept® by Roche, and as the sodium salt Myfortic® by Novartis. It was approved by the FDA in 2000.

Statins are the most successful medicines in history as measured by the number of prescriptions filled and revenues generated. Worldwide sales are predicted to amount to 1 trillion dollars by 2020.<sup>(28)</sup> Approximately one in three people take a statin.<sup>(28)</sup>

The first statins to be discovered were Compactin and Mevacor, found from *Penicillium compactum* and *Aspergillus terreus* respectively. These compounds were initially discovered as cholesterol biosynthesis inhibitors and subsequently shown to affect hydroxymethylglutaryl coenzyme A reductase (HMG-CoA reductase). Medicinal chemistry has led to the synthesis of a number of superior analogues which are currently on the market.

Pravastatin, a statin formed by the stereoselective microbial hydroxylation of Compactin, was discovered by Sankyo Pharma in the 1970s.<sup>(29)</sup> In the US, it is marketed as Pravachol® by Bristol-Myers Squibb. Sales of Pravachol® reached 1.3 billion dollars in the US in 2005.<sup>(30)</sup>

Candidas®, also a cyclic peptide, was discovered from the fungus *Glarea lozoyensis* and developed by Merck in the 1990s.<sup>(31)</sup> Candidas® represented a new class of antifungal agents that inhibit glucan biosynthesis.

The most recent fungal metabolite derivative to be introduced clinically is Fingolimod, also known by the trade name Gilenya®

and marketed by Novartis. It was approved in 2011 for the treatment of multiple sclerosis.<sup>(32, 33)</sup> Fingolimod is a synthetic derivative of myriocin, a powerful immunosuppressant and a metabolite from *Isaria sinclairii*, a type of *Cordyceps*.<sup>(32, 33)</sup> *Isaria sinclairii* is the name of the anamorph, and *Cordyceps sinclairii*, which colonizes insects, is the name of the teleomorph. The culture broth of this fungus was used in traditional Chinese medicine as an “eternal youth” elixir.<sup>(32, 34)</sup>

In summary, the bioactivity of fungal metabolites has been known for at least 12 centuries and, based on contemporary research, has led to the development of some of the most important drugs of the 21st century.

#### **References:**

1. Ma, Jiyuan, et al. “Constituents of red yeast rice, a traditional Chinese food and medicine.” *Journal of Agricultural and Food Chemistry* 48.11 (2000): 5220-5225.
2. Endo, Akira. “The origin of the statins.” *International Congress Series*. Vol. 1262. Elsevier, 2004.
3. Díaz, José Luis. “Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico.” *Annual Review of Pharmacology and Toxicology* 17.1 (1977): 647-675.
4. MacReady, Norra. “Opening doors of perception: Psychedelic drugs and end-of-life care.” *Journal of the National Cancer Institute* (2012) 104 (21): 1619-1620.
5. Fleming, Alexander. “On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*.” *British Journal of Experimental Pathology* 10.3 (1929): 226.
6. Moyer, Andrew J., and Robert D. Coghill. “Penicillin: IX. The Laboratory Scale Production of Penicillin in Submerged Cultures by *Penicillium notatum* Westling (NRRL 832) 1.” *Journal of Bacteriology* 51.1 (1946): 79.
7. Barrios-Gonzalez, J., et al. “Penicillin production by solid state fermentation.” *Biotechnology Letters* 10.11 (1988): 793-798.
8. Bo, G. “Giuseppe Brotzu and the discovery of cephalosporins.” *Clinical Microbiology and Infection* 6 (2000): 6-8.
9. Whitby, Michael. “Fusidic acid in the treatment of methicillin-resistant *Staphylococcus aureus*.” *International Journal of Antimicrobial Agents* 12 (1999): S67-S71.
10. Andlauer, Wilfried, and Peter Fürst. “Nutraceuticals: a piece of history, present status and outlook.” *Food Research International* 35.2 (2002): 171-176.
11. Markova, Nadya, et al. “Effects of intraperitoneal and intranasal application of Lentinan on cellular response in rats.” *International Immunopharmacology* 2.12 (2002): 1641-1645.

12. Yang, Hyun, et al. "Lentinus edodes promotes fat removal in hypercholesterolemic mice." *Experimental And Therapeutic Medicine* 6 (2013): 1409-1413.
13. Graham, J. R., and Harold G. Wolff. "Mechanism of migraine headache and action of ergotamine tartrate." *Archives of Neurology & Psychiatry* 39.4 (1938): 737-763.
14. Stoll, Arthur. "Introductory remarks on ergotamine." *International Archives of Allergy and Immunology* 7.4-6 (1955): 197-204.
15. Koehler, P. J., and H. Isler. "The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception." *Cephalalgia* 22.8 (2002): 686-691.
16. Diener, H-C., et al. "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison." *European Neurology* 47.2 (2002): 99-107.
17. Kornfeld, Edmund C., et al. "The total synthesis of lysergic acid." *Journal of the American Chemical Society* 78 (1956): 3087-3114.
18. Hoffmann, Albert. "LSD—My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science." trans. J. Ott. JP Tarcher. [AVS] (1983).
19. Ross, Stephen, et al. "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial." *Journal of Psychopharmacology* 30.12 (2016): 1165-1180.
20. Griffiths, Roland R., and Charles S. Grob. "Hallucinogens as medicine." *Scientific American* 303.6 (2010): 76-79.
21. Kurland, Albert A. "LSD in the supportive care of the terminally ill cancer patient." *Journal of Psychoactive Drugs* 17.4 (1985): 279-290.
22. Gasser, Peter, Katharina Kirchner, and Torsten Passie. "LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects." *Journal of Psychopharmacology* (2014): 0269881114555249.
23. Borel, J. F., Z. L. Kis, and T. Beveridge. "The History of the Discovery and Development of Cyclosporine (Sandimmune®)." *The Search for Anti-Inflammatory Drugs*. Birkhäuser Boston, (1995): 27-63.
24. "Natural Products: Drug Discovery and Therapeutic Medicine" Lixin Zhang and Arnold Demain Humana Press Totowa NJ, 2005 ISBN# 1-58829-383-1
25. Chen, Huifang, Anlun Ma, and Pierre Daloze. "Historical remarks of immunosuppressive therapy in organ transplantation." *Current Immunosuppressive Therapy In Organ Transplantation* (2015): 51.
26. Franklin, T. J., and Jennifer M. Cook. "The inhibition of nucleic acid synthesis by mycophenolic acid." *Biochemical Journal* 113.3 (1969): 515-524.
27. Eugui, E. M., et al. "Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion." *Scandinavian Journal of Immunology* 33.2 (1991): 161-173.
28. Ioannidis JP. "More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines." *Journal of the American Medical Association*. (2014): 311: 463-464.
29. Daniewski, A. R., P. M. Wovkulich, and M. R. Uskokovic. "Remote diastereoselection in the asymmetric synthesis of pravastatin." *The Journal of Organic Chemistry* 57.26 (1992): 7133-7139.
30. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108644.htm> Laura Alvey April 24, 2006
31. James M. Balkovec, David L. Hughes, Prakash S. Masurekar, Carole A. Sable, Robert E. Schwartz, Sheo B. Singh. "Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study." *Natural Product Reports* (2014): 31, 15-34.
32. Cherilyn R. Strader, Cedric J. Pearce, and Nicholas H. Oberlies. "Fingolimod (FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite." *Journal of Natural Products* (2011): 74, 900-907.
33. T. Fujita, K. Inoue, S. Yamamoto, T. Ikumoto, S. Sasaki, R. Toyama, K. Chiba, Y. Hoshino, T. Okumoto, "Fungal metabolites. Part 11. A potent immunosuppressive activity found in *Isaria sinclairii* metabolite." *The Journal of Antibiotics* (1994): 47: 208-215.
34. Chiang Su New Medical College (Ed): *Dictionary of Chinese Crude Drug*. pp. 767-768, Shanghai Scientific Technologic Publisher, Shanghai, 1985

**Table 1:**

Compound	Derived Product	Producing Fungus	Application	Projected Annual Sales (2017)	Sales References	
<b>Compactin</b>	Mevastatin	Penicillium compactum	cholesterol lowering agent	never marketed		
<b>Mevacor</b>	Lovastatin	Aspergillus terreus	cholesterol lowering agent	\$1 Billion	5	
<b>Pravastatin</b>	Pravachol	Penicillium compactum	cholesterol lowering agent	\$1.3 Billion	9	US only
<b>Penicillins</b>	Penicillins	Penicillium notatum	bacterial infections	\$8.2 Billion	1	global
<b>Co-amoxiclav</b>	Augmentin	(Actinomycetes)	bacterial infections	\$1 Billion	6	global
<b>Cephalosporins</b>	Cephalosporins	Cephalosporium	bacterial infections	\$9.9 Billion	1	global
<b>Fusidic Acid</b>	Fucidin	Fusidium coccineum	bacterial infections			
<b>Psilocybin</b>	Psilocybin	Psilocybe mexicana	terminal illness	never marketed		
<b>Lysergic Acid</b>	LSD	Claviceps purpurea	terminal illness	never marketed		
<b>Cyclosporin A</b>	Cyclosporin A	Tolyptocladium inflatum	organ transplantation	\$1 Billion	1	
<b>Mycophenolic Acid</b>	Myfortic, CellCept	Penicillium stoloniferum	organ transplantation	\$306.8 Million	2	US only
<b>Caspofungin</b>	Cancidas	Glarea lozoyensis	fungal infections	\$611 Million	3	
<b>Fingolimod</b>	Gilenya	Isaria sinclairii	multiple sclerosis	\$2.5 Billion	4	
<b>Shiitake mushrooms</b>	Lentinan	Letinula edodes	cancer treatment and prevention, cholesterol lowering agent, immunostimulation, anti-infectious agent	\$75 Million	7	shiitake and oyster US produced only
<b>Ergot</b>	Ergotamine	Claviceps purpurea	migraine headaches			
<b>Strobilurins</b>	Strobilurins	Stobilurus tenacellus	agricultural fungicides	\$3.8 Billion	8	global

**Table 1 References:**

1. Natural Products: Drug Discovery and Therapeutic Medicine Lixin Zhang and Arnold Demain Humana Press Totowa NJ, 2005 ISBN# 1-58829-383-1
2. <http://www.news-medical.net/news/20140109/Mylan-announces-launch-of-Mycophenolic-Acid-Delayed-release-Tablets.aspx> Mylan Inc. January 9, 2014
3. <https://www.law360.com/articles/229176/merk-teva-end-cancidas-patent-fight> Samuel Howard March 2, 2011
4. <http://www.fiercepharma.com/legal/early-gilenya-generics-now-spell-trouble-for-rival-ms-drugs> Tracy Staton October 5, 2015
5. Nature Reviews and Drug Discovery Vol. 2 July, 2003 pg. 517-526 Jonathan A. Tobert
6. <http://www.pharmalive.com/glaxosmithkline-plc-2014/> October 1, 2014 Andrew Humphreys
7. <http://www.thepacker.com/marketing-profiles/mushroom-marketing/sales-keep-growing-all-mushroom-categories> January 14, 2016 Jim Offner
8. China Strobilurin Fungicides Market Report 2016 Edition Research and Markets Business Wire November 23, 2016
9. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108644.htm> Laura Alvey April 24, 2006